Attached files
| file | filename |
|---|---|
| EX-4.1 - FORM OF CONVERTIBLE PROMISSORY NOTE - RELMADA THERAPEUTICS, INC. | f10q1217ex4-1_relmada.htm |
| EX-32.1 - CERTIFICATION - RELMADA THERAPEUTICS, INC. | f10q1217ex32-1_relmadatherap.htm |
| EX-31.2 - CERTIFICATION - RELMADA THERAPEUTICS, INC. | f10q1217ex31-2_relmadatherap.htm |
| EX-31.1 - CERTIFICATION - RELMADA THERAPEUTICS, INC. | f10q1217ex31-1_relmadatherap.htm |
| EX-10.1 - FORM OF NOTE AND WARRANT PURCHASE AGREEMENT - RELMADA THERAPEUTICS, INC. | f10q1217ex10-1_relmada.htm |
| EX-4.2 - FORM OF WARRANT TO PURCHASE COMMON STOCK - RELMADA THERAPEUTICS, INC. | f10q1217ex4-2_relmada.htm |
| 10-Q - QUARTERLY REPORT - RELMADA THERAPEUTICS, INC. | f10q1217_relmadatherapeutics.htm |
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Relmada Therapeutics, Inc. (the “Company”) on Form 10-Q for the three months ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sergio Traversa, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Quarterly Report fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company. |
| Relmada Therapeutics, Inc. | ||
| By: | /s/ Sergio Traversa | |
| Sergio Traversa | ||
Chief Executive Officer and Interim Chief Financial Officer |
||
February 12, 2018